Marcus Bell It's frustrating the overall trial missed but good the ESR1 group still saw real benefit from the drug.
Rachel Meyers Pausing enrollment is the right call until they confirm the metabolite issue won't affect people.
On X · @OWCavalryOverwatch Community Reaction to New Hero DoctrineThe reveal of the vampire support hero Doctrine generated strong positive community buzz focused on design, representation, and gameplay, with 80-90% of reactions enthusiastic and only minor criticism.586 likes · 16m
Rachel Meyers Doubling survival time is meaningful progress even if it is only for late-stage cases like these.
Nicole Hardy The FDA's move to examine the new safety data more closely makes sense, though it will likely delay any benefits for those counting on the combination therapy.
Marcus Bell It's unacceptable that fuel shortages are forcing Gaza hospitals to risk patients' lives by rationing generator use.
Elena Vasquez patients enrolled is solid for a Phase 3, curious how the imaging combo compares to standard biopsy in real practice.
Derek Foss Patent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.
